<?xml version='1.0' encoding='utf-8'?>
<document id="10727880"><sentence text="Pharmacokinetic interaction trial between co-artemether and mefloquine."><entity charOffset="60-70" id="DDI-PubMed.10727880.s1.e0" text="mefloquine" /></sentence><sentence text="Forty-two healthy subjects were randomized in a parallel three-group design trial to investigate potential electrocardiographic and pharmacokinetic interactions between the new antimalarial co-artemether, a combination of artemether and lumefantrine (both of which are predominantly metabolized through CYP3A4), and mefloquine, another antimalarial described as a substrate (and possible inhibitor) of CYP3A4"><entity charOffset="222-232" id="DDI-PubMed.10727880.s2.e0" text="artemether" /><entity charOffset="237-249" id="DDI-PubMed.10727880.s2.e1" text="lumefantrine" /><entity charOffset="316-326" id="DDI-PubMed.10727880.s2.e2" text="mefloquine" /><pair ddi="false" e1="DDI-PubMed.10727880.s2.e0" e2="DDI-PubMed.10727880.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10727880.s2.e0" e2="DDI-PubMed.10727880.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10727880.s2.e0" e2="DDI-PubMed.10727880.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10727880.s2.e1" e2="DDI-PubMed.10727880.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10727880.s2.e1" e2="DDI-PubMed.10727880.s2.e2" /></sentence><sentence text=" Subjects were assigned to one of the three possible treatment groups (i" /><sentence text="e" /><sentence text=", co-artemether alone or mefloquine alone or the combination of both)"><entity charOffset="25-35" id="DDI-PubMed.10727880.s5.e0" text="mefloquine" /></sentence><sentence text=" The dosage was 1000 mg mefloquine (divided into three doses over 12 h) followed 12 h later by six applications of co-artemether (40 mg artemether+480 mg lumefantrine each) over 60 h"><entity charOffset="24-34" id="DDI-PubMed.10727880.s6.e0" text="mefloquine" /><entity charOffset="154-166" id="DDI-PubMed.10727880.s6.e1" text="lumefantrine" /><pair ddi="false" e1="DDI-PubMed.10727880.s6.e0" e2="DDI-PubMed.10727880.s6.e0" /><pair ddi="false" e1="DDI-PubMed.10727880.s6.e0" e2="DDI-PubMed.10727880.s6.e1" /></sentence><sentence text=" The study medications were generally well tolerated after all treatments" /><sentence text=" Concomitant administration with mefloquine caused statistically significant lower (around 30-40%) plasma concentrations of lumefantrine than when co-artemether was administered alone"><entity charOffset="33-43" id="DDI-PubMed.10727880.s8.e0" text="mefloquine" /><entity charOffset="124-136" id="DDI-PubMed.10727880.s8.e1" text="lumefantrine" /><pair ddi="false" e1="DDI-PubMed.10727880.s8.e0" e2="DDI-PubMed.10727880.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10727880.s8.e0" e2="DDI-PubMed.10727880.s8.e1" /></sentence><sentence text=" Even if important, this decrease in lumefantrine exposure was considered unlikely to impact clinical efficacy given the wide therapeutic index of co-artemether and the usual high variability in lumefantrine plasma levels, mostly and more importantly influenced by food intake"><entity charOffset="37-49" id="DDI-PubMed.10727880.s9.e0" text="lumefantrine" /><entity charOffset="195-207" id="DDI-PubMed.10727880.s9.e1" text="lumefantrine" /><pair ddi="false" e1="DDI-PubMed.10727880.s9.e0" e2="DDI-PubMed.10727880.s9.e0" /><pair ddi="false" e1="DDI-PubMed.10727880.s9.e0" e2="DDI-PubMed.10727880.s9.e1" /></sentence><sentence text=" However, patients should be encouraged to eat at dosing times to compensate for this decreased bioavailability" /><sentence text=" The pharmacokinetics of artemether, DHA or mefloquine were not affected"><entity charOffset="25-35" id="DDI-PubMed.10727880.s11.e0" text="artemether" /><entity charOffset="37-40" id="DDI-PubMed.10727880.s11.e1" text="DHA" /><entity charOffset="44-54" id="DDI-PubMed.10727880.s11.e2" text="mefloquine" /><pair ddi="false" e1="DDI-PubMed.10727880.s11.e0" e2="DDI-PubMed.10727880.s11.e0" /><pair ddi="false" e1="DDI-PubMed.10727880.s11.e0" e2="DDI-PubMed.10727880.s11.e1" /><pair ddi="false" e1="DDI-PubMed.10727880.s11.e0" e2="DDI-PubMed.10727880.s11.e2" /><pair ddi="false" e1="DDI-PubMed.10727880.s11.e1" e2="DDI-PubMed.10727880.s11.e1" /><pair ddi="false" e1="DDI-PubMed.10727880.s11.e1" e2="DDI-PubMed.10727880.s11.e2" /></sentence><sentence text=" Artemether concentrations significantly decreased over doses, independently of mefloquine co-administration, while DHA concentrations slightly (not significantly) increased"><entity charOffset="80-90" id="DDI-PubMed.10727880.s12.e0" text="mefloquine" /><entity charOffset="116-119" id="DDI-PubMed.10727880.s12.e1" text="DHA" /><pair ddi="false" e1="DDI-PubMed.10727880.s12.e0" e2="DDI-PubMed.10727880.s12.e0" /><pair ddi="false" e1="DDI-PubMed.10727880.s12.e0" e2="DDI-PubMed.10727880.s12.e1" /></sentence><sentence text=" Therefore, no clinically relevant risks due to pharmacokinetic drug-drug interaction are expected at the enzymatic level following co-administration of co-artemether with CYP3A4 substrates with similar affinity to that of mefloquine"><entity charOffset="223-233" id="DDI-PubMed.10727880.s13.e0" text="mefloquine" /></sentence><sentence text="" /></document>